Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72

Raymond James analyst Tiago Fauth has initiated coverage on Quince Therapeutics (NASDAQ: QNCX) with an Outperform rating. The firm has set a price target of $72 for the company's stock.